JPRN-UMIN000025922已完成1 期
Safety and pharmacokinetics of single and repeated dose of intra-nasal TTA-121 in healthy volunteers (Phase 1 trial). - Safety and pharmacokinetics of single and repeated dose of intra-nasal TTA-121 in healthy volunteers (Phase 1 trial).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 35years-old（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) no history of therapeutic use of oxytocin 2) no history of hypersensitivity of oxytocin 3) no family history of male breast cancer 4) no history or existing condition such as hematological, renal, endocrinological, respiratory, GI tract, cardiovascular, liver, psychological or neurological disease. 5) existing condition which may affect drug absorption, metabolism or secretion. 6) rhinitis or other nasal condition which causes difficulties in intranasal administration. 7) no prior participation and receiving experimental drugs in other clinical trials within 3 months. 8)not suitable to enroll based on medical reasons.
研究者
相似试验
暂停
1 期
A study in healthy Japanese men to test how different doses of BI 894416 are toleratedJPRN-jRCT2080225328ippon Boehringer Ingelheim Co., Ltd.24
招募中
1 期
A study in healthy Japanese men to test how well different dosesof BI 1569912 are toleratedMajor Dipressive DisorderJPRN-jRCT2071210037Furuichi Takumi44
尚未招募
1 期
A study in healthy Japanese men to test how well different doses of BI 764198 are toleratedAJPRN-jRCT2071200055Ogawa Shintaro44
已完成
1 期
A study in healthy Japanese men to test how different doses of BI 1323495 are tolerated and how itraconazole influences the amount of BI 1323495 in the bloodJPRN-jRCT2071200056Katakabe Tetsuya74
进行中（未招募）
不适用
The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to see what the best dose should be for children in the future. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug.o medical condition specified as the purpose of this study is to describe the pharmacokinetics of moxifloxacin in children for future antibiotic treatment.EUCTR2012-000737-40-Outside-EU/EEABayer HealthCare Pharmaceuticals36